- (b) detecting binding of the antibody, or antibody fragment thereof, to the Fkh^{sf} polypeptide.
- 21. (Amended) The method of any one of claims 20, 35-36 wherein said antibody is selected from the group consisting of:
 - (a) polyclonal antibody,
 - (b) a murine monoclonal antibody,
 - (c) a humanized antibody derived from (b),
 - (d) a human monoclonal antibody, and
- 22. (Amended) The method of any one of claims 20, 35-36, wherein said antibody fragment is selected from the group consisting of F(ab')₂, F(ab)₂, Fab', Fab, Fv, sFv, and minimal recognition unit.
- 23. (Amended) The method of any one of claims 20, 35-36, wherein said antibody or said antibody fragment further comprises a detectable label selected from the group consisting of radioisotope, fluorescent label, chemiluminescent label, enzyme label, bioluminescent label, and colloidal gold.

Please add new claims 35-36 to read as follows:



- 35. (New) A method for detecting the presence of an FKH^{sf} polypeptide in a biological sample, comprising the steps of:
- (a) contacting the biological sample with an antibody, or an antibody fragment thereof, that specifically binds to an FKH^{sf} polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:4, under conditions that allow binding of the antibody or antibody fragment to the FKH^{sf} polypeptide, and
- (b) detecting binding of the antibody, or antibody fragment thereof, to the FKH^{sf} polypeptide.